Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 9—September 2024
Research
Medical Costs of Nontuberculous Mycobacterial Pulmonary Disease, South Korea, 2015–2019
Table 4
Cost analysis of the treatment of nontuberculous mycobacterial pulmonary disease, South Korea, 2015–2019*
| Variable | Cumulative cost† |
Out-of-pocket costs |
Annual cost‡ |
Per visit§ |
|---|---|---|---|---|
| Median (IQR) | Median (IQR) | Median (IQR) | Media, (IQR) | |
| All visits, n = 147 | ||||
| Total | 5,044 (3,586–9,680) | 2,535 (1,779–4,087) | 1,319 (845–2,478) | NA |
| Nonbenefit | 115 (13–431) | 115 (13–497) | 28 (3–109) | NA |
| Medication | 1,197 (656–2,728) | 362 (214–872) | 296 (178–676) | NA |
| Diagnostic tests | 3,006 (2,134–4,511) | 1,536 (1,152–2,332) | 701(536– 1,199) | NA |
| Clinical services | 616 (416–1,749) | 426 (312–839) | 140 (106–481) | NA |
*Currency in US $, rounded to the nearest dollar. IQR, interquartile range; NA, not applicable. †All costs pertaining to each category of visit. ‡Cumulative cost divided by the duration of total follow-up in years. §Cumulative cost for outpatients divided by the number of outpatient visits. ¶Cumulative cost of admission divided by the number of admissions.
1These first authors contributed equally to this article.
2These authors were co–principal investigators.
Page created: July 30, 2024
Page updated: August 13, 2024
Page reviewed: August 13, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.